Cardio Diagnostics Holdings (NASDAQ: CDIO), an artificial intelligence-driven precision cardiovascular medicine company, has released a whitepaper addressing diagnostic challenges in non-obstructive coronary artery disease (NOCAD), a condition where patients experience coronary disease symptoms without significant blockages in major arteries. The report critically examines the limitations of invasive coronary angiography, which assesses coronary anatomy rather than function, and highlights ischemia with no obstructive coronary arteries (INOCA), a condition affecting an estimated 3 million to 4 million Americans. This announcement is significant because it underscores a often-overlooked patient population and proposes a shift toward earlier, non-invasive detection methods that could improve outcomes and reduce healthcare costs.
The whitepaper outlines NOCAD subgroups, diagnostic pathways, and opportunities to enhance detection of coronary disease that conventional angiography may miss. It also discusses clinical approaches to identify patients earlier, including the potential role of epigenetics-based testing in primary care settings. Cardio Diagnostics highlights its ongoing efforts to build clinical evidence for PrecisionCHD, its AI- and epigenetics-based blood test designed to aid in diagnosing coronary heart disease, including its potential application in identifying patients with INOCA whose symptoms remain unexplained by traditional testing. For investors and stakeholders, this release signals the company's commitment to addressing unmet clinical needs and expanding its precision medicine portfolio. The full press release is available at https://ibn.fm/N5RnS, and the latest updates relating to CDIO can be found in the company’s newsroom at https://ibn.fm/CDIO.
The whitepaper's focus on NOCAD and INOCA is timely, as these conditions often go undiagnosed due to reliance on anatomical imaging that fails to detect functional impairments. By advocating for epigenetics-based testing, Cardio Diagnostics positions itself at the forefront of a paradigm shift in cardiovascular diagnostics. The company's AI-driven Integrated Genetic-Epigenetic Engine aims to make cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. This approach could lead to earlier interventions, better patient stratification, and reduced reliance on invasive procedures. The announcement was disseminated through BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences sectors, which is part of the Dynamic Brand Portfolio at IBN. BioMedWire provides access to a vast network of wire solutions via InvestorWire, including editorial syndication to 5,000+ outlets and social media distribution, ensuring that important developments like this reach a wide audience of investors, influencers, and healthcare professionals. For more information, visit www.BioMedWire.com.


